Who is sponsoring NCT06653010?

NCT06653010 is sponsored by Wondercel Biotech (ShenZhen).

What drugs are being tested in NCT06653010?

Interventions in NCT06653010: Universal CAR-T cells injection for treating mCRC.

What condition does NCT06653010 study?

NCT06653010 studies CRC (Colorectal Cancer), Metastatic Colorectal Cancer.

Is NCT06653010 still recruiting?

NCT06653010 is currently recruiting now. Last updated 16 January 2026.

Last reviewed 2026-01-16 · How we verify

NCT06653010: Wondercel-UWD1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer

Recruiting now EARLY_PHASE1 Last updated 16 January 2026

What this trial tests

EARLY_PHASE1 trial testing Universal CAR-T cells injection for treating mCRC in CRC (Colorectal Cancer) in 30 participants. Currently enrolling.

Timeline

23 October 2024

Primary endpoint
20 October 2027

30 December 2027

Quick facts

Lead sponsor	Wondercel Biotech (ShenZhen)
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	23 October 2024
Primary completion	20 October 2027
Estimated completion	30 December 2027
Sites	2 locations across China

Drugs / interventions tested

Universal CAR-T cells injection for treating mCRC — full drug profile →

Conditions studied

CRC (Colorectal Cancer) — all drugs for CRC (Colorectal Cancer) →
Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →

Sponsor

Wondercel Biotech (ShenZhen) — full company profile →

Who can join

Adults 18 to 75, any sex, with CRC (Colorectal Cancer) or Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.
Khelwatty SA, Puvanenthiran S, Seddon AM, Bagwan I, et al · · 2025 · cited 1× · PMID 40940907 · DOI 10.3390/cancers17172810
Advances and challenges of chimeric antigen receptor T cell therapy in digestive system malignancies.
Wang C, Zhang J, Chen ZK, Wang YG, et al · · 2026 · PMID 41810338 · DOI 10.5306/wjco.v17.i2.114107
Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.
Kim SY. · · 2026 · PMID 41802306 · DOI 10.3393/ac.2025.01354.0193
Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications.
Sayed MS, Gadelmawla AF, Abouelenin O, Moubarak ES, et al · · 2025 · PMID 40974479 · DOI 10.1007/s12032-025-03040-5

Verify or expand the search:

Other recruiting trials for CRC (Colorectal Cancer)

Currently open trials in the same condition.

NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting
NCT07254910 — Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma · NA · recruiting
NCT07478731 — Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07153458 — Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer · recruiting
NCT07376707 — A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic S · Phase 1 · recruiting

Other Wondercel Biotech (ShenZhen) trials

Trials by the same sponsor.

NCT06663046 — Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT06675513 — Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer · EARLY_PHASE1 · recruiting
NCT06662227 — Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors · EARLY_PHASE1 · recruiting
NCT06653023 — Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06653010 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wondercel Biotech (ShenZhen)
Last refreshed: 16 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06653010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing